Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL258223 | 0.82 | ALDH1A1 (0.55) | L3MBTL1POLBSMN1; SMN2LMNAMAPT | |
| SCHEMBL2129407 | 0.80 | SMN1; SMN2 (0.59) | L3MBTL1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL15738996 | 0.80 | KMT2A (0.53) | L3MBTL1KMT2ASMN1; SMN2LMNAMAPT | |
| SCHEMBL7118948 | 0.78 | MAPT (0.51) | L3MBTL1POLBKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL6842191 | 0.77 | TSHR (0.64) | POLBKMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL2478054 | 0.76 | KDM4E (0.50) | L3MBTL1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL8314979 | 0.76 | SMN1; SMN2 (0.46) | L3MBTL1SMN1; SMN2LMNAMAPTKDM4E | |
| SCHEMBL2750299 | 0.76 | KDM5A (0.51) | L3MBTL1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL4906930 | 0.75 | TDP1 (0.59) | L3MBTL1POLBSMN1; SMN2LMNAMAPT | |
| SCHEMBL4906925 | 0.75 | TDP1 (0.59) | L3MBTL1POLBSMN1; SMN2LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278103-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2016-03-08 | — | — | US | disclosed |
| US-9168259-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | Grünenthal GmbH (DE) | 2015-10-27 | — | — | US | disclosed |
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2014-07-31 | — | — | US | disclosed |
| US-8552200-B2 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | GRUNENTHAL GMBH (DE) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213569-A1 | Substituted 6-amino-nicotinamides as KCNQ2/3 modulators | KCNQ2, KCNQ1, KCNQ3 | L3MBTL1 3212/4885POLB 3986/4885KMT2A 403/4885 |
| US-20120101079-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | L3MBTL1 3212/4885POLB 3986/4885KMT2A 403/4885 |
| US-20120258947-A1 | SUBSTITUTED 6-AMINO-NICOTINAMIDES AS KCNQ2/3 MODULATORS | KCNQ2, KCNQ1, KCNQ3 | L3MBTL1 3212/4885POLB 3986/4885KMT2A 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.